By M. Marin
NASDAQ:PYPD
Innovative Drug Delivery Platform (PLEX Technology)
PolyPid Ltd. (NASDAQ:PYPD) is a late clinical stage biopharma company focused on developing locally administered, prolonged-release therapeutics using its proprietary Polymer-Lipid Encapsulation matriX (PLEX) technology, which enables the controlled delivery of medications directly at the surgical site over extended periods ranging from days to several months. The PLEX delivery system is designed to improve surgical outcomes and enhance the efficacy of treatments while minimizing side effects. PolyPid's lead asset is D-PLEX100, which it is studying for the treatment of patients undergoing abdominal surgery.
The PLEX platform is flexible and can deliver a variety of therapies, including small molecules, proteins, peptides, and nucleic acids. In addition to studying the efficacy of D-PLEX100 in treating abdominal surgery patients, the company also expects to study it for the treatment of patients who require orthopedic surgery. PolyPid also has OncoPLEX in its product pipeline for treatment in oncology patients undergoing surgery.
Advancing Lead Candidate D-PLEX100 Through Clinical Trials
PolyPid's lead asset, D-PLEX100, is a novel formulation intended to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery. The company is currently conducting a pivotal Phase 3 clinical trial of D-PLEX100, SHIELD (Surgical site Hospital acquired Infection prEvention with Local D-PLEX) II.
SHIELD II is a randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX100 alongside standard of care therapies compared to standard of care alone in preventing post abdominal-surgery incisional infection in patients with large incisions.
In March 2025, PolyPid announced the successful completion of patient enrollment in the SHIELD II trial. The trial enrolled 800 patients in medical centers in the U.S., Europe and Israel. The independent Data Safety Monitoring Board (DSMB) had recommended that PolyPid conclude enrollment at the lowest sample size reassessment option, as it believes it will be sufficient to provide statistical significance of the potential positive efficacy of D-PLEX100. The company viewed the DSMB’s enrollment recommendation as a positive that suggests the positive efficacy signals from D-PLEX100 and believes the study has been derisked significantly. Importantly, to date, no safety issues related to D-PLEX100 have been observed in the SHIELD II trial.
The company expects to report top-line results by the end of 2Q25. Depending on the top-line results, PolyPid intends to submit an NDA (New Drug Application) to the FDA in early 2026 to leverage D-PLEX100 Fast Track and Breakthrough Therapy designations and thereby expedite the path to potential regulatory approval.
Pursuing strategic commercial and R&D collaborations
In 2022, PolyPid formed an exclusive licensing agreement with UK-based ADVANZ PHARMA Corp. for the commercialization of D-PLEX100 in Europe. Moreover, PolyPid is actively pursuing partnerships to enhance the commercial introduction of D-PLEX100 in the U.S. The company has indicated that it is in advanced discussions with several potential partners to maximize the commercialization of D-PLEX100 if/when it receives regulatory approval. PolyPid estimates the target market for D-PLEX100 at potential commercial launch in the U.S. and Europe at more than seven million abdominal surgeries.
The company believes that 2025 could be a transformational year. Depending on top-line data from the SHIELD II Phase 3 trial, it not only expects to advance clinical activities, but also anticipates the potential for a sizable cash infusion. Warrants from the company’s recent financing could generate an incremental up to $27.0 million in capital if exercised in full. These warrants expire within 10 business days following the publication of SHIELD II top-line results. If this occurs, PolyPid anticipates the warrant exercise could extend its cash runway into and beyond the potential approval on its NDA application in 2026.
The company is also exploring licensing opportunities to expand its platform technology and product candidates globally. In addition, PolyPid has entered into an R&D collaboration with ImmunoGenesis to develop novel treatments for solid tumors, leveraging its PLEX technology.
Risks
PolyPid faces several risks including the risk that clinical trials are not successful and do not lead to regulatory approval, that the company will not have sufficient cash to advance its research activities and will have to raise capital that could be dilutive to existing shareholders and that market competition could increase.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.